GHRP-2 (Pralmorelin): preparation and storage
Intended for research use only. Not a medicinal product.
Contents (11 sections)
GHRP-2 has its own sequence
GHRP-2, or pralmorelin, is a synthetic hexapeptide secretagogue active at the ghrelin receptor GHS-R1a. It is a different molecule from GHRP-6; the number does not denote concentration or purification grade. Check non-natural and D-residues, C-terminal amidation, expected mass and salt form. It is not a human growth hormone fragment. Equal milligrams of two GHRPs need not represent equal molecule numbers, so molar comparison requires confirmed molecular weights for each form.
Pralmorelin as a separate calibrator
Pralmorelin links GHRP-2 to its chemical reference identity but does not establish a commercial mixture’s composition. With another secretagogue present, receptor response is combined and cannot quantify GHRP-2 separately. Use an identified single-component standard with a known mass-labeling convention. In LC-MS, check carryover when related GHRPs are analyzed sequentially. Signal in a blank after concentrated standard requires carryover correction rather than a biological-activity explanation.
A comparative model does not establish a universal ranking
Raun’s study compared GHRP-2 with GHRP-6 and ipamorelin. Swine assessments included GH-stimulation potency, maximum effect and other hormonal responses. The activity order belongs to that model and endpoint. Different GHS-R1a expression or readouts require renewed ranking checks. Batch assessment needs a GHRP-2 reference and method reproducibility limits. Another agonist helps check the biological system but cannot replace a chemically identical standard.
Solution checks must include transfer
GHRP-2 contains aromatic and non-natural residues; its short chain alone cannot predict aqueous behavior. Check the specification and a small solvent trial, then recovery after transfer to receptor-assay buffer. Protein composition can change the available fraction and adsorption. In low-concentration series, compare recovery before and after plate contact if quantitative analysis permits. An acid or organic additive used in stock needs separate final-system controls even when its fraction seems small.
Mass calculations and working dilutions
An arithmetic example, not a solubility prescription: 2 mg in a final volume of 4 mL gives 0.5 mg/mL, or 500 micrograms/mL. Adding 20 microliters of that stock to 980 microliters of compatible matrix gives 10 micrograms/mL. Then 100 microliters of this solution plus 900 microliters of matrix gives 1 microgram/mL. Use the final volume in the calculation. If the certificate separately establishes peptide mass fraction, apply it according to the labeling convention, without correcting the mass twice. Molarity requires the molecular weight of the confirmed form; do not borrow a value from a related analogue.
Separate potency from maximum effect
In Raun and colleagues’ comparison of ipamorelin, GHRP-6 and GHRP-2, potency and maximum response depended on the model. A lower concentration for a particular response does not establish a higher maximum effect in every system. Batch checks require a concentration-response curve rather than one point. GHS-R1a signaling and GH secretion in a pituitary model answer different questions. When ACTH or cortisol are relevant in a complex model, measure them separately; a GH profile alone cannot establish reagent “purity.”
Correct mass does not complete identification
D-residues make stereochemistry relevant to GHRP-2. Mass spectrometry establishes mass but not each residue’s configuration by itself. Supply checks need a consistent structure, verified standard and impurity profile. An additional storage-related peak cannot be identified merely as a “peptide impurity.” Compare retention and mass, using further structural analysis where necessary. Only then can chemical change, another secretagogue and analytical artifacts be distinguished.
Comparison and storage questions
Can GHRP-2 replace GHRP-6 without retuning the assay? A new curve and identity check are needed. Does absence of cloudiness guarantee an equal available concentration? Adsorbed material is not visible. Does an old sample’s weaker signal establish degradation? Cell state, matrix changes or surface losses could explain it. Check fresh control, chemical recovery and receptor response in the same series. Frozen dry-GHRP-2 stability does not establish stability of its working dilution in culture medium.
GHRP-2 in a multicomponent medium
Culture samples contain serum proteins and peptides alongside GHRP-2. Total UV absorbance is not GHRP-2 quantity; use a specific method with a matrix blank. Record contact time before readout, or fresh/stored differences can be confused with stimulation kinetics. Store dry stocks frozen as specified and validate the solution’s working interval. Adding another GHRP or GHRH analogue creates a new multicomponent experiment rather than preserving the original reagent.
End of article
GHRP-2
for laboratory research
Packs and current prices on the product page.